nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—CYP2C9—cardial valve—dilated cardiomyopathy	0.0834	0.353	CbGeAlD
Bosentan—Hepatic cirrhosis—Furosemide—dilated cardiomyopathy	0.0285	0.0504	CcSEcCtD
Bosentan—EDNRB—cardiac ventricle—dilated cardiomyopathy	0.0257	0.109	CbGeAlD
Bosentan—EDNRB—myocardium—dilated cardiomyopathy	0.0241	0.102	CbGeAlD
Bosentan—EDNRA—cardiac ventricle—dilated cardiomyopathy	0.0212	0.0899	CbGeAlD
Bosentan—Glucose tolerance impaired—Furosemide—dilated cardiomyopathy	0.0203	0.0359	CcSEcCtD
Bosentan—EDNRA—myocardium—dilated cardiomyopathy	0.02	0.0845	CbGeAlD
Bosentan—EDNRB—heart—dilated cardiomyopathy	0.0169	0.0714	CbGeAlD
Bosentan—EDNRB—cardiac atrium—dilated cardiomyopathy	0.0144	0.061	CbGeAlD
Bosentan—EDNRA—heart—dilated cardiomyopathy	0.0139	0.059	CbGeAlD
Bosentan—EDNRA—cardiac atrium—dilated cardiomyopathy	0.0119	0.0505	CbGeAlD
Bosentan—Atrioventricular block complete—Lisinopril—dilated cardiomyopathy	0.0117	0.0208	CcSEcCtD
Bosentan—EDNRB—Endothelin Pathways—ADRB1—dilated cardiomyopathy	0.01	0.0505	CbGpPWpGaD
Bosentan—Lethargy—Spironolactone—dilated cardiomyopathy	0.00745	0.0132	CcSEcCtD
Bosentan—EDNRA—Endothelin Pathways—ADRB1—dilated cardiomyopathy	0.00717	0.0361	CbGpPWpGaD
Bosentan—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00657	0.0116	CcSEcCtD
Bosentan—Disturbance in attention—Furosemide—dilated cardiomyopathy	0.00631	0.0112	CcSEcCtD
Bosentan—Eosinophilia—Spironolactone—dilated cardiomyopathy	0.00624	0.011	CcSEcCtD
Bosentan—Gout—Furosemide—dilated cardiomyopathy	0.00586	0.0104	CcSEcCtD
Bosentan—EDNRB—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.00583	0.0294	CbGpPWpGaD
Bosentan—EDNRA—EGFR-dependent Endothelin signaling events—EGFR—dilated cardiomyopathy	0.00579	0.0292	CbGpPWpGaD
Bosentan—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00558	0.00986	CcSEcCtD
Bosentan—Haemoptysis—Lisinopril—dilated cardiomyopathy	0.00554	0.0098	CcSEcCtD
Bosentan—Renal failure—Spironolactone—dilated cardiomyopathy	0.00553	0.00977	CcSEcCtD
Bosentan—EDNRB—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.00542	0.0273	CbGpPWpGaD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00511	0.0258	CbGpPWpGaD
Bosentan—Bladder pain—Furosemide—dilated cardiomyopathy	0.00494	0.00874	CcSEcCtD
Bosentan—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00477	0.00844	CcSEcCtD
Bosentan—CYP2C9—heart—dilated cardiomyopathy	0.00461	0.0195	CbGeAlD
Bosentan—EDNRB—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.00448	0.0226	CbGpPWpGaD
Bosentan—Gout—Lisinopril—dilated cardiomyopathy	0.00439	0.00777	CcSEcCtD
Bosentan—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00422	0.00747	CcSEcCtD
Bosentan—EDNRB—Endothelin Pathways—RAF1—dilated cardiomyopathy	0.00418	0.0211	CbGpPWpGaD
Bosentan—Thirst—Furosemide—dilated cardiomyopathy	0.00417	0.00738	CcSEcCtD
Bosentan—EDNRA—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.00417	0.021	CbGpPWpGaD
Bosentan—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00415	0.00734	CcSEcCtD
Bosentan—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.0041	0.00726	CcSEcCtD
Bosentan—Lethargy—Furosemide—dilated cardiomyopathy	0.00405	0.00716	CcSEcCtD
Bosentan—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00401	0.00709	CcSEcCtD
Bosentan—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00399	0.00705	CcSEcCtD
Bosentan—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.00399	0.00705	CcSEcCtD
Bosentan—Wheezing—Lisinopril—dilated cardiomyopathy	0.00399	0.00705	CcSEcCtD
Bosentan—Cystitis—Lisinopril—dilated cardiomyopathy	0.00396	0.00701	CcSEcCtD
Bosentan—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00393	0.00696	CcSEcCtD
Bosentan—Fluid retention—Lisinopril—dilated cardiomyopathy	0.0039	0.00689	CcSEcCtD
Bosentan—EDNRA—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.00388	0.0196	CbGpPWpGaD
Bosentan—Photophobia—Lisinopril—dilated cardiomyopathy	0.00385	0.00681	CcSEcCtD
Bosentan—Irritability—Furosemide—dilated cardiomyopathy	0.00379	0.0067	CcSEcCtD
Bosentan—EDNRB—Endothelins—RAC1—dilated cardiomyopathy	0.00375	0.0189	CbGpPWpGaD
Bosentan—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00371	0.00656	CcSEcCtD
Bosentan—Discomfort—Spironolactone—dilated cardiomyopathy	0.0037	0.00654	CcSEcCtD
Bosentan—Dehydration—Furosemide—dilated cardiomyopathy	0.00369	0.00653	CcSEcCtD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00366	0.0184	CbGpPWpGaD
Bosentan—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.00365	0.00646	CcSEcCtD
Bosentan—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00363	0.00641	CcSEcCtD
Bosentan—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00361	0.00639	CcSEcCtD
Bosentan—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00359	0.00634	CcSEcCtD
Bosentan—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00357	0.00632	CcSEcCtD
Bosentan—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00351	0.00621	CcSEcCtD
Bosentan—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00345	0.00611	CcSEcCtD
Bosentan—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.00341	0.00603	CcSEcCtD
Bosentan—Eosinophilia—Furosemide—dilated cardiomyopathy	0.0034	0.00601	CcSEcCtD
Bosentan—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00336	0.00594	CcSEcCtD
Bosentan—Eczema—Lisinopril—dilated cardiomyopathy	0.00331	0.00586	CcSEcCtD
Bosentan—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00331	0.00586	CcSEcCtD
Bosentan—EDNRA—GPCRs, Other—CXCR3—dilated cardiomyopathy	0.00329	0.0166	CbGpPWpGaD
Bosentan—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.00327	0.00578	CcSEcCtD
Bosentan—EDNRA—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.00321	0.0162	CbGpPWpGaD
Bosentan—Somnolence—Spironolactone—dilated cardiomyopathy	0.00319	0.00564	CcSEcCtD
Bosentan—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00317	0.0056	CcSEcCtD
Bosentan—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00314	0.00556	CcSEcCtD
Bosentan—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00313	0.00553	CcSEcCtD
Bosentan—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.0031	0.00547	CcSEcCtD
Bosentan—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.0031	0.00547	CcSEcCtD
Bosentan—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00305	0.0054	CcSEcCtD
Bosentan—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00304	0.00537	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00303	0.00536	CcSEcCtD
Bosentan—Renal failure—Furosemide—dilated cardiomyopathy	0.00301	0.00532	CcSEcCtD
Bosentan—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00299	0.00529	CcSEcCtD
Bosentan—EDNRA—Endothelin Pathways—RAF1—dilated cardiomyopathy	0.00299	0.0151	CbGpPWpGaD
Bosentan—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00298	0.00527	CcSEcCtD
Bosentan—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00296	0.00523	CcSEcCtD
Bosentan—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00289	0.00512	CcSEcCtD
Bosentan—Urticaria—Spironolactone—dilated cardiomyopathy	0.00285	0.00504	CcSEcCtD
Bosentan—Irritability—Lisinopril—dilated cardiomyopathy	0.00284	0.00503	CcSEcCtD
Bosentan—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00284	0.00501	CcSEcCtD
Bosentan—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.00283	0.00501	CcSEcCtD
Bosentan—Dehydration—Lisinopril—dilated cardiomyopathy	0.00277	0.0049	CcSEcCtD
Bosentan—EDNRB—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.00274	0.0138	CbGpPWpGaD
Bosentan—EDNRB—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.00274	0.0138	CbGpPWpGaD
Bosentan—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00272	0.00481	CcSEcCtD
Bosentan—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00271	0.0048	CcSEcCtD
Bosentan—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00269	0.00476	CcSEcCtD
Bosentan—EDNRA—Endothelins—RAC1—dilated cardiomyopathy	0.00269	0.0135	CbGpPWpGaD
Bosentan—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00268	0.00474	CcSEcCtD
Bosentan—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00266	0.00471	CcSEcCtD
Bosentan—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00264	0.00467	CcSEcCtD
Bosentan—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.0026	0.00459	CcSEcCtD
Bosentan—EDNRA—GPCRs, Other—ADRB2—dilated cardiomyopathy	0.00258	0.013	CbGpPWpGaD
Bosentan—Asthma—Lisinopril—dilated cardiomyopathy	0.00257	0.00455	CcSEcCtD
Bosentan—Influenza—Lisinopril—dilated cardiomyopathy	0.00257	0.00455	CcSEcCtD
Bosentan—Eye disorder—Furosemide—dilated cardiomyopathy	0.00257	0.00454	CcSEcCtD
Bosentan—Tinnitus—Furosemide—dilated cardiomyopathy	0.00256	0.00453	CcSEcCtD
Bosentan—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.00255	0.00451	CcSEcCtD
Bosentan—EDNRB—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.00255	0.0128	CbGpPWpGaD
Bosentan—Pruritus—Spironolactone—dilated cardiomyopathy	0.00254	0.00449	CcSEcCtD
Bosentan—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.00253	0.00448	CcSEcCtD
Bosentan—Sweating increased—Lisinopril—dilated cardiomyopathy	0.00251	0.00443	CcSEcCtD
Bosentan—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00251	0.00443	CcSEcCtD
Bosentan—Angiopathy—Furosemide—dilated cardiomyopathy	0.00249	0.00441	CcSEcCtD
Bosentan—EDNRB—Endothelins—RAF1—dilated cardiomyopathy	0.00249	0.0126	CbGpPWpGaD
Bosentan—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00248	0.00439	CcSEcCtD
Bosentan—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00248	0.00438	CcSEcCtD
Bosentan—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00245	0.00434	CcSEcCtD
Bosentan—Dysuria—Lisinopril—dilated cardiomyopathy	0.00241	0.00426	CcSEcCtD
Bosentan—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00241	0.00426	CcSEcCtD
Bosentan—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00239	0.00423	CcSEcCtD
Bosentan—Erythema—Furosemide—dilated cardiomyopathy	0.00239	0.00423	CcSEcCtD
Bosentan—Malnutrition—Furosemide—dilated cardiomyopathy	0.00239	0.00423	CcSEcCtD
Bosentan—Dizziness—Spironolactone—dilated cardiomyopathy	0.00237	0.00419	CcSEcCtD
Bosentan—Flatulence—Furosemide—dilated cardiomyopathy	0.00236	0.00417	CcSEcCtD
Bosentan—Weight increased—Lisinopril—dilated cardiomyopathy	0.00234	0.00414	CcSEcCtD
Bosentan—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00233	0.00412	CcSEcCtD
Bosentan—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00232	0.00411	CcSEcCtD
Bosentan—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00231	0.00408	CcSEcCtD
Bosentan—Muscle spasms—Furosemide—dilated cardiomyopathy	0.0023	0.00406	CcSEcCtD
Bosentan—Vomiting—Spironolactone—dilated cardiomyopathy	0.00228	0.00403	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00228	0.00402	CcSEcCtD
Bosentan—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00226	0.004	CcSEcCtD
Bosentan—Rash—Spironolactone—dilated cardiomyopathy	0.00226	0.004	CcSEcCtD
Bosentan—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00226	0.00399	CcSEcCtD
Bosentan—Renal failure—Lisinopril—dilated cardiomyopathy	0.00226	0.00399	CcSEcCtD
Bosentan—Vision blurred—Furosemide—dilated cardiomyopathy	0.00225	0.00398	CcSEcCtD
Bosentan—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00225	0.00398	CcSEcCtD
Bosentan—Headache—Spironolactone—dilated cardiomyopathy	0.00225	0.00397	CcSEcCtD
Bosentan—Jaundice—Lisinopril—dilated cardiomyopathy	0.00224	0.00396	CcSEcCtD
Bosentan—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00223	0.00395	CcSEcCtD
Bosentan—Anaemia—Furosemide—dilated cardiomyopathy	0.00221	0.00391	CcSEcCtD
Bosentan—Haematuria—Lisinopril—dilated cardiomyopathy	0.00219	0.00387	CcSEcCtD
Bosentan—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00217	0.00384	CcSEcCtD
Bosentan—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00217	0.00383	CcSEcCtD
Bosentan—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00215	0.00381	CcSEcCtD
Bosentan—Vertigo—Furosemide—dilated cardiomyopathy	0.00215	0.0038	CcSEcCtD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00215	0.0108	CbGpPWpGaD
Bosentan—Leukopenia—Furosemide—dilated cardiomyopathy	0.00214	0.00378	CcSEcCtD
Bosentan—EDNRB—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.00213	0.0108	CbGpPWpGaD
Bosentan—Nausea—Spironolactone—dilated cardiomyopathy	0.00213	0.00377	CcSEcCtD
Bosentan—EDNRB—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.00211	0.0106	CbGpPWpGaD
Bosentan—Bradycardia—Lisinopril—dilated cardiomyopathy	0.0021	0.00371	CcSEcCtD
Bosentan—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00206	0.00364	CcSEcCtD
Bosentan—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00204	0.0036	CcSEcCtD
Bosentan—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00203	0.00359	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00202	0.00357	CcSEcCtD
Bosentan—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00202	0.00357	CcSEcCtD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00199	0.0101	CbGpPWpGaD
Bosentan—Dry mouth—Furosemide—dilated cardiomyopathy	0.00199	0.00352	CcSEcCtD
Bosentan—EDNRA—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.00196	0.00989	CbGpPWpGaD
Bosentan—EDNRA—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.00196	0.00989	CbGpPWpGaD
Bosentan—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00195	0.00345	CcSEcCtD
Bosentan—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00195	0.00344	CcSEcCtD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00193	0.00974	CbGpPWpGaD
Bosentan—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00192	0.0034	CcSEcCtD
Bosentan—Shock—Furosemide—dilated cardiomyopathy	0.00192	0.00339	CcSEcCtD
Bosentan—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00191	0.00338	CcSEcCtD
Bosentan—Flushing—Lisinopril—dilated cardiomyopathy	0.00191	0.00338	CcSEcCtD
Bosentan—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00191	0.00338	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.00191	0.00963	CbGpPWpGaD
Bosentan—Skin disorder—Furosemide—dilated cardiomyopathy	0.0019	0.00335	CcSEcCtD
Bosentan—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00189	0.00334	CcSEcCtD
Bosentan—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00187	0.00331	CcSEcCtD
Bosentan—Anorexia—Furosemide—dilated cardiomyopathy	0.00186	0.00329	CcSEcCtD
Bosentan—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00186	0.00328	CcSEcCtD
Bosentan—Chills—Lisinopril—dilated cardiomyopathy	0.00185	0.00327	CcSEcCtD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00184	0.00927	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00184	0.00927	CbGpPWpGaD
Bosentan—EDNRA—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.00182	0.0092	CbGpPWpGaD
Bosentan—Hypotension—Furosemide—dilated cardiomyopathy	0.00182	0.00322	CcSEcCtD
Bosentan—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00181	0.00319	CcSEcCtD
Bosentan—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00179	0.00317	CcSEcCtD
Bosentan—Erythema—Lisinopril—dilated cardiomyopathy	0.00179	0.00317	CcSEcCtD
Bosentan—EDNRA—Endothelins—RAF1—dilated cardiomyopathy	0.00178	0.00898	CbGpPWpGaD
Bosentan—Flatulence—Lisinopril—dilated cardiomyopathy	0.00177	0.00313	CcSEcCtD
Bosentan—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00175	0.0031	CcSEcCtD
Bosentan—Back pain—Lisinopril—dilated cardiomyopathy	0.00174	0.00307	CcSEcCtD
Bosentan—Somnolence—Furosemide—dilated cardiomyopathy	0.00173	0.00307	CcSEcCtD
Bosentan—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00172	0.00305	CcSEcCtD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00171	0.00862	CbGpPWpGaD
Bosentan—Decreased appetite—Furosemide—dilated cardiomyopathy	0.0017	0.003	CcSEcCtD
Bosentan—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00169	0.00299	CcSEcCtD
Bosentan—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00168	0.00298	CcSEcCtD
Bosentan—Fatigue—Furosemide—dilated cardiomyopathy	0.00168	0.00297	CcSEcCtD
Bosentan—Tremor—Lisinopril—dilated cardiomyopathy	0.00168	0.00297	CcSEcCtD
Bosentan—Pain—Furosemide—dilated cardiomyopathy	0.00167	0.00295	CcSEcCtD
Bosentan—Constipation—Furosemide—dilated cardiomyopathy	0.00167	0.00295	CcSEcCtD
Bosentan—Anaemia—Lisinopril—dilated cardiomyopathy	0.00166	0.00293	CcSEcCtD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00166	0.00835	CbGpPWpGaD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00165	0.00832	CbGpPWpGaD
Bosentan—Angioedema—Lisinopril—dilated cardiomyopathy	0.00164	0.0029	CcSEcCtD
Bosentan—Vertigo—Lisinopril—dilated cardiomyopathy	0.00161	0.00285	CcSEcCtD
Bosentan—Syncope—Lisinopril—dilated cardiomyopathy	0.00161	0.00284	CcSEcCtD
Bosentan—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00161	0.00284	CcSEcCtD
Bosentan—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.0016	0.00282	CcSEcCtD
Bosentan—Palpitations—Lisinopril—dilated cardiomyopathy	0.00159	0.0028	CcSEcCtD
Bosentan—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00158	0.00279	CcSEcCtD
Bosentan—Cough—Lisinopril—dilated cardiomyopathy	0.00157	0.00277	CcSEcCtD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.00157	0.00789	CbGpPWpGaD
Bosentan—Urticaria—Furosemide—dilated cardiomyopathy	0.00155	0.00274	CcSEcCtD
Bosentan—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00154	0.00273	CcSEcCtD
Bosentan—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00154	0.00273	CcSEcCtD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00154	0.00774	CbGpPWpGaD
Bosentan—EDNRA—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.00153	0.0077	CbGpPWpGaD
Bosentan—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00153	0.0027	CcSEcCtD
Bosentan—Chest pain—Lisinopril—dilated cardiomyopathy	0.00153	0.0027	CcSEcCtD
Bosentan—Anxiety—Lisinopril—dilated cardiomyopathy	0.00152	0.00269	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00152	0.00268	CcSEcCtD
Bosentan—Discomfort—Lisinopril—dilated cardiomyopathy	0.00151	0.00267	CcSEcCtD
Bosentan—EDNRA—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.00151	0.00761	CbGpPWpGaD
Bosentan—EDNRB—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.0015	0.00757	CbGpPWpGaD
Bosentan—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00149	0.00264	CcSEcCtD
Bosentan—EDNRB—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.00148	0.00748	CbGpPWpGaD
Bosentan—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00146	0.00259	CcSEcCtD
Bosentan—Oedema—Lisinopril—dilated cardiomyopathy	0.00146	0.00259	CcSEcCtD
Bosentan—Infection—Lisinopril—dilated cardiomyopathy	0.00145	0.00257	CcSEcCtD
Bosentan—Shock—Lisinopril—dilated cardiomyopathy	0.00144	0.00255	CcSEcCtD
Bosentan—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00144	0.00254	CcSEcCtD
Bosentan—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00143	0.00253	CcSEcCtD
Bosentan—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00143	0.00253	CcSEcCtD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00143	0.0072	CbGpPWpGaD
Bosentan—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00142	0.00251	CcSEcCtD
Bosentan—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00142	0.0025	CcSEcCtD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00141	0.00713	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.0014	0.00708	CbGpPWpGaD
Bosentan—Asthenia—Furosemide—dilated cardiomyopathy	0.0014	0.00248	CcSEcCtD
Bosentan—EDNRB—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.0014	0.00706	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.0014	0.00706	CbGpPWpGaD
Bosentan—Anorexia—Lisinopril—dilated cardiomyopathy	0.0014	0.00247	CcSEcCtD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00138	0.00697	CbGpPWpGaD
Bosentan—Pruritus—Furosemide—dilated cardiomyopathy	0.00138	0.00244	CcSEcCtD
Bosentan—Hypotension—Lisinopril—dilated cardiomyopathy	0.00137	0.00242	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.00137	0.00689	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.00134	0.00677	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00134	0.00676	CbGpPWpGaD
Bosentan—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00134	0.00236	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00133	0.00236	CcSEcCtD
Bosentan—Insomnia—Lisinopril—dilated cardiomyopathy	0.00132	0.00234	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.00132	0.00666	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00132	0.00663	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00132	0.00663	CbGpPWpGaD
Bosentan—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00131	0.00232	CcSEcCtD
Bosentan—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00131	0.00231	CcSEcCtD
Bosentan—Somnolence—Lisinopril—dilated cardiomyopathy	0.0013	0.0023	CcSEcCtD
Bosentan—EDNRB—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.0013	0.00656	CbGpPWpGaD
Bosentan—Dizziness—Furosemide—dilated cardiomyopathy	0.00129	0.00228	CcSEcCtD
Bosentan—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00129	0.00228	CcSEcCtD
Bosentan—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00127	0.00225	CcSEcCtD
Bosentan—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00126	0.00223	CcSEcCtD
Bosentan—Fatigue—Lisinopril—dilated cardiomyopathy	0.00126	0.00223	CcSEcCtD
Bosentan—EDNRB—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00126	0.00636	CbGpPWpGaD
Bosentan—Constipation—Lisinopril—dilated cardiomyopathy	0.00125	0.00221	CcSEcCtD
Bosentan—Pain—Lisinopril—dilated cardiomyopathy	0.00125	0.00221	CcSEcCtD
Bosentan—Vomiting—Furosemide—dilated cardiomyopathy	0.00124	0.00219	CcSEcCtD
Bosentan—Rash—Furosemide—dilated cardiomyopathy	0.00123	0.00218	CcSEcCtD
Bosentan—Dermatitis—Furosemide—dilated cardiomyopathy	0.00123	0.00217	CcSEcCtD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00122	0.00617	CbGpPWpGaD
Bosentan—Headache—Furosemide—dilated cardiomyopathy	0.00122	0.00216	CcSEcCtD
Bosentan—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.0012	0.00212	CcSEcCtD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00118	0.00597	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00118	0.00595	CbGpPWpGaD
Bosentan—Urticaria—Lisinopril—dilated cardiomyopathy	0.00116	0.00206	CcSEcCtD
Bosentan—Nausea—Furosemide—dilated cardiomyopathy	0.00116	0.00205	CcSEcCtD
Bosentan—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00116	0.00205	CcSEcCtD
Bosentan—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00116	0.00205	CcSEcCtD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.00112	0.00565	CbGpPWpGaD
Bosentan—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00108	0.00191	CcSEcCtD
Bosentan—EDNRB—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.00108	0.00543	CbGpPWpGaD
Bosentan—EDNRA—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.00108	0.00542	CbGpPWpGaD
Bosentan—EDNRA—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.00106	0.00535	CbGpPWpGaD
Bosentan—Asthenia—Lisinopril—dilated cardiomyopathy	0.00105	0.00186	CcSEcCtD
Bosentan—Pruritus—Lisinopril—dilated cardiomyopathy	0.00104	0.00183	CcSEcCtD
Bosentan—EDNRB—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.00102	0.00515	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00101	0.0051	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.001	0.00505	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.001	0.00505	CbGpPWpGaD
Bosentan—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.001	0.00177	CcSEcCtD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000995	0.00502	CbGpPWpGaD
Bosentan—Dizziness—Lisinopril—dilated cardiomyopathy	0.000968	0.00171	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000961	0.00485	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00096	0.00484	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000932	0.0047	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000931	0.0047	CbGpPWpGaD
Bosentan—Vomiting—Lisinopril—dilated cardiomyopathy	0.000931	0.00165	CcSEcCtD
Bosentan—Rash—Lisinopril—dilated cardiomyopathy	0.000923	0.00163	CcSEcCtD
Bosentan—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000922	0.00163	CcSEcCtD
Bosentan—Headache—Lisinopril—dilated cardiomyopathy	0.000917	0.00162	CcSEcCtD
Bosentan—EDNRA—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000902	0.00455	CbGpPWpGaD
Bosentan—Nausea—Lisinopril—dilated cardiomyopathy	0.00087	0.00154	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000791	0.00399	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000791	0.00399	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.00077	0.00389	CbGpPWpGaD
Bosentan—CYP2C9—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000758	0.00382	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000758	0.00382	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000736	0.00371	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000731	0.00369	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000718	0.00362	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000718	0.00362	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000712	0.00359	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000712	0.00359	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000668	0.00337	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000667	0.00336	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000647	0.00326	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000639	0.00322	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ANKRD1—dilated cardiomyopathy	0.000625	0.00315	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000608	0.00307	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—TAZ—dilated cardiomyopathy	0.000588	0.00296	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000577	0.00291	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000566	0.00286	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000566	0.00286	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000552	0.00279	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000542	0.00273	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—SDHA—dilated cardiomyopathy	0.000532	0.00268	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000526	0.00265	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000524	0.00264	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000514	0.00259	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000514	0.00259	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.00051	0.00257	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000478	0.00241	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000478	0.00241	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000469	0.00236	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000463	0.00233	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000458	0.00231	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000448	0.00226	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000441	0.00222	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000435	0.0022	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000428	0.00216	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000424	0.00214	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000424	0.00214	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000413	0.00208	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000407	0.00205	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000395	0.00199	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000395	0.00199	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000389	0.00196	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000382	0.00193	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000375	0.00189	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000342	0.00173	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000326	0.00165	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000324	0.00164	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000321	0.00162	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000316	0.00159	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.00031	0.00156	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000306	0.00154	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000304	0.00153	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000304	0.00153	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000291	0.00147	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000284	0.00143	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000282	0.00142	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000278	0.0014	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000273	0.00138	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.00027	0.00136	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000266	0.00134	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—RAC1—dilated cardiomyopathy	0.00024	0.00121	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000234	0.00118	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AGT—dilated cardiomyopathy	0.00023	0.00116	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000222	0.00112	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	0.000209	0.00105	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	0.000196	0.00099	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000193	0.000974	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.00019	0.00096	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000185	0.000933	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	0.000178	0.000895	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000172	0.000867	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AGT—dilated cardiomyopathy	0.000164	0.000829	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000159	0.000804	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GPX1—dilated cardiomyopathy	0.000144	0.000728	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CD36—dilated cardiomyopathy	0.000141	0.000709	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000138	0.000694	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000132	0.000668	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000129	0.000653	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—AGT—dilated cardiomyopathy	0.000127	0.000639	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	0.000117	0.00059	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000114	0.000575	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000109	0.000551	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000108	0.000546	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000105	0.000532	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	9.5e-05	0.000479	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EGFR—dilated cardiomyopathy	7.82e-05	0.000394	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	4.82e-05	0.000243	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	4.7e-05	0.000237	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	4.23e-05	0.000213	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	3.18e-05	0.00016	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	3.1e-05	0.000156	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.79e-05	0.000141	CbGpPWpGaD
